Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/306598


Analytical Tool - Current & Future Therapies for Colorectal Cancer


Description: "Analytical Tool - Current & Future Therapies for Colorectal Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal (CRC) R&D and business development. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers - Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight and Colorectal Cancer Drug Pipeline Update 2007-.

The Package Includes

A progress analysis on current and emerging drugs
Information on most companies active in CRC R&D
Information on key industry related CRC projects
Data from most important clinical trials
Information on early developmental stage projects
Possibility of performing advanced searches suited to your individual needs
This Tool will Assist You in:

Tracking cutting edge companies, therapies and new technologies
Rapid identification of partners & competitors
Laying down a comprehensive framework for further analysis of the field
Producing presentations surrounding the development of CRC therapeutics
Identifying emerging CRC products & key areas of pharmaceutical R&D
-BioSeekers CD-ROM searchable database reflects the most recent advances in the field of CRC drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker Group CD-ROM searchable databases is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker Group’s CD-ROM searchable databases give better overview and specific search capabilities.


Contents: Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight

2 Executive Summary

3 Cancer Highlights

4 Methodology

5 List of Contents

5.1 List of Boxes
5.2 List of Figures
5.3 List of Tables

6 Epidemiology

6.1 Disease Definition
6.2 Prognosis for Colorectal Cancer by Stage

7 Drugs on Market

7.1 A 50% Increase in Sales!
7.2 Topoisomerase inhibitor in First-line and Second-line Treatment
7.3 Fast Way to Approval
7.4 A Significant Reduction in the Risk of Death
7.5 Mice and Men
7.6 The Very Base

8 Key Drug Strategies in CRC

8.1 Apoptosis
8.1.1 An Answer to Drug Resistance
8.1.2 Novel Therapies at the Gate
8.2 Tumor Vascularization & Antivascular Agents
8.2.1 Anti-angiogenesis: Therapeutic Strategies
8.2.2 Single Agent Therapy: Poorly Active in Advanced Tumors.
8.2.3 Synergistic Effects with Cytotoxic Therapies
8.2.4 Vascular Targeting Agents
8.3 Vaccines
8.3.1 Tumor antigens
8.3.2 The Cell Vaccines Strategy
8.3.3 Potent antigen presenting cells
8.3.4 Emerging strategies

9 Competitive Landscape in CRC Drug Development

9.1 We are in the Lead
9.1.1 Amgen
9.1.2 Novartis and Schering
9.1.3 OSI, Genentech, Hoffmann La Roche & Pfizer
9.1.4 Sanofi-Aventis

10 Current CRC Drug Development

10.1 Chemotherapy and Cytotoxic Drugs - A strategy reborn
10.1.1 Progress Analysis: CoFactor
10.1.2 Progress Analysis: Trabectedin (ET-743)
10.1.3 Progress Analysis: Pemetrexed
10.1.4 Progress Analysis: TS-1
10.1.5 Progress Analysis: Edotecarin
10.1.6 Progress Analysis: Aroplatin
10.1.7 Progress Analysis: Ixabepilone
10.2 EGF-R Inhibition and Other Signal Transduction Inhibitors
10.2.1 Progress Analysis: Panitumumab
10.2.2 Progress Analysis: Erlotinib (Tarceva)
10.2.3 Progress Analysis: Gefitinib (Iressa)
10.2.4 Progress Analysis: Pelitinib
10.2.5 Progress Analysis: Sorafenib
10.3 Signal Transduction Inhibitors in CRC
10.3.1 Progress Analysis: BIO-117
10.3.2 Progress Analysis: PD 0325901
10.4 Antiangiogenetic- A team of players
10.4.1 Progress Analysis: Vatalanib
10.4.2 Progress Analysis: Thalidomide
10.4.3 Progress Analysis: AMG 706
10.4.4 Progress Analysis: Combretastatin A4 prodrug
10.4.5 Progress Analysis: MBT 0206
10.4.6 Progress Analysis: MEDI 522
10.4.7 Progress Analysis: Tetrathiomolybdate
10.4.8 Progress Analysis: WX-UK1
10.5 COX-2 Inhibitors - What will become of us?
10.5.1 Progress Analysis: P 54
10.5.2 Progress Analysis: CV-247
10.6 Apoptosis: An approach with a future
10.6.1 Progress Analysis: HGS-ETR1
10.6.2 Progress Analysis: APLIDIN
10.6.3 Progress Analysis: VELCADE
10.6.4 Progress Analysis: TELCYTA
10.6.5 Progress Analysis EPO 906
10.6.6 Progress Analysis: BIO-145
10.6.7 Progress Analysis: Genasense
10.6.8 Progress Analysis: Rexin-G
10.6.9 Progress Analysis: Indisulam
10.6.10 Progress Analysis: Seliciclib
10.6.11 Progress Analysis: SYMADEX
10.7 Necrotic Cell Death Inducers
10.7.1 Progress Analysis: RAV12
10.7.2 Progress Analysis: Cantuzumab mertansine
10.7.3 Progress Analysis: HuC242-DM4
10.7.4 Progress Analysis: COTARA
10.8 Vaccines: A high Threshold to Success
10.8.1 Cell Vaccine
10.8.2 Vaccine: Direct Immunization with Protein and peptides
10.8.3 Anti-idiotype Monoclonal Antibodies
10.8.4 DNA and Virally Encoded Vaccines
10.8.5 Passive Immunotherapy and Conjugated Antibodies
10.9 Immuno-modulators
10.9.1 Progress Analysis: Dacogen
10.9.2 Progress Analysis: GCAN-101
10.9.3 Progress Analysis: ZYC300
10.9.4 Progress Analysis: Clofarabine
10.10 Oncolytic Virotherapy in CRC - A team of four
10.10.1 Progress Analysis: OncoVEX
10.10.2 Progress Analysis: Oncolytic HSV

11 Disclaimer

12 Appendix I: Treatment Guide Lines

12.1.1 Medical Therapy of Colorectal Cancer

13 Appendix II: Selected Company Profiles

14 Drug Index

15 Company Index

5.1 List of Boxes

Box 1:Example of Observed Efficacy in preclinical models
Box 2: Anti-angiogenesis: Therapeutic strategies.
Box 3: Anti-angiogenesis: Problems that has to be solved
Box 4: Mechanisms which tumor cells use to evade an immune reaction
Box 5: Quick Facts - ANX-510
Box 6: Quick Facts - Trabectedin
Box 7: Quick Facts - Pemetrexed
Box 8: Quick Facts - TS-1
Box 9: Quick Facts - Edotecarin
Box 10: Quick Facts - Aroplatin
Box 11: Quick Facts - Ixabepilone
Box 12: Quick Facts - Panitumumab
Box 13: Quick Facts - Erlotinib
Box 14: Scientific Data on Erlotinib
Box 15: Quick Facts - Gefitinib
Box 16: Scientific Data on Gefitinib
Box 17: Quick Facts - Pelitinib
Box 18: Quick Facts - Sorafenib
Box 19: Quick Facts - BIO-117
Box 20: Quick Facts - PD 0325901
Box 21: Quick Facts - Vatalanib
Box 22: Quick Facts - Thalomide
Box 23: Quick Facts - AMG 706
Box 24: Quick Facts - Combretastatin
Box 25: Quick Facts - MBT 0206
Box 26: Quick Facts - MEDI 522
Box 27: Quick Facts - Tetrathiomolybdate
Box 28: Quick Facts - WX-UK1
Box 29: Quick Facts - P 54
Box 30: Quick Facts - CV-247
Box 31: Targets for Apoptosis Directed Therapy
Box 32: Selection of Patents Relating to Apoptosis
Box 33: Quick Facts - HGS-ETR1
Box 34: Quick Facts - APLIDIN
Box 35: Quick Facts - VELCADE
Box 36: Millenniums License Agreement with Ortho Biotech
Box 37: Quick Facts - TELCYTA
Box 38: Quick Facts - EPO 906
Box 39: Quick Facts - BIO-145
Box 40: Quick Facts - Genasense
Box 41: Quick Facts - Rexin-G
Box 42: Quick Facts - Indisulam
Box 43: Quick Facts - Seliciclib
Box 44: Quick Facts - SYMANDEX
Box 45: Quick Facts - RAV12
Box 46: Quick Facts - Cantuzumab mertansine
Box 47: Quick Facts - HuC242-DM4
Box 48: Quick Facts - Cotara
Box 49: Quick Facts - OncoVAX
Box 50: Quick Facts - Canvaxin
Box 51: Quick Facts - Collidem
Box 52: Quick Facts - Dendricell
Box 53: Quick Facts - Neuvenge
Box 54: Quick Facts - Onyvax-CR
Box 55: Quick Facts - Ras-VAX
Box 56: Quick Facts - Avicine
Box 57: Quick Facts - Oncophage
Box 58: Quick Facts - EP 2101
Box 59: Quick Facts - MSI Vaccine
Box 60: Quick Facts - MUC-vaccine
Box 61: Quick Facts - OncoVAX
Box 62: Quick Facts - CeaVac
Box 63: Quick Facts - Onyvax-105
Box 64: Quick Facts - TroVax
Box 65: Quick Facts - ALVA-CEA-B7.1
Box 66: Quick Facts - CEA-TRICOM
Box 67: Quick Facts - IR 705
Box 68 Quick Facts - Amplivax
Box 69: Quick Facts - IGN 101
Box 70: Quick Facts - CEA-Cide
Box 71: Quick Facts - LMB 9
Box 72: Quick Facts - KSB 303
Box 73: Quick Facts - ING-1
Box 74: Quick Facts -Dacogen
Box 75: Quick Facts - GCAN-101
Box 76: Quick Facts - ZYC300
Box 77: Quick Facts - Clofarabine
Box 78: Quick Facts - OncoVEX
Box 79: Quick Facts - NV 1020

5.2 List of Figures

5.3 List of Tables

Table 1: 5-year Survival Rate in CRC
Table 2: Risk Factors for Colon Cancer Development
Table 3: Summary of Colorectal Cancer Regimens
Table 4: Summary of Chemotherapy Drugs
Table 5: Capecitabine - Major Developmental Milestones
Table 6: Ironotecan - Major Developmental Milestones
Table 7: Bevacizumab - Major Developmental Milestones
Table 8: Sales Predictions on Bevacizumab
Table 9: Oxaliplatin - Major Developmental Milestones
Table 10: Cetuximab - Major Developmental Milestones
Table 11: Sales Predictions on Cetuximab
Table 12: Common Gene/Protein Defects in Apoptotic Pathways
Table 13: A Selection of Apoptosis Targets in Development
Table 14: Selection of VTA agents under clinical development as cancer therapeutics
Table 15: Colorectal Cancer Vaccines in Development
Table 16: The Representation of Investigators in the CRC Drug Pipeline
Table 17: Drugs with Four or more Investigators
Table 18: Phase III Competitors
Table 19: Industrial Investigators with the Highest Number of CRC Drugs in Phase I to Phase III development
Table 20: Phase I -Phase III Chemotherapy and Cytotoxic Drugs in Development
Table 21: Phase I-Phase III EGF-R Inhibitors as CRC Therapeutics
Table 22: Phase I-Phase III Signal Transduction Inhibitors in CRC
Table 23: Phase I - Phase III Antiangiogenic Drugs in Development
Table 24: Current COX-2 Inhibitors in Development
Table 25: Apoptotic Cell Death Inducers in Development
Table 26: Necrotic Cell Death Inducers in Development
Table 27 Cell therapy based platform in pipeline as potential treatment of colorectal cancer
Table 28: Protein/peptide vaccine as potential treatment of colorectal cancer
Table 29: Anti-idiotype monoclonal antibodies
Table 30: Nucleic acid and virally encoded vaccines
Table 31: Monoclonal Antibodies
Table 32: Immuno-modulators in CRC




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/306598

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 30/08/2008 07:05:12
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Analytical Tool - Current & Future Therapies for Colorectal Cancer
Web Address:
http://www.researchandmarkets.com/reports/306598
Office Code:
OCHGMJKKNUX

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €3,100.00
Electronic (PDF) - Site License €6,200.00
Electronic (PDF) - Enterprisewide €9,300.00




Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646)607-1907 or (646)964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 30/08/2008 07:05:12

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646)607-1907 or (646)964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World